Pixium Vision confirms human implantation and activation of PRIMA

Pixium Vision, Company committed to curating bionic vision systems ensuring revival of lost sight to patients, asserted the world’s first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss from atrophic dry Age-related Macular Degeneration (AMD). This study is designed to evaluate the safety and performance of PRIMA in eliciting central visual perception among patients who have lost their central sight due to atrophic advanced dry-AMD. The study will recruit up to 5 patients with evaluation at 6-month follow-up and longer-term follow-up to 36 months. This enables the patient to start the re-education phase as per the trial protocol, which includes a 6-month follow-up and progress update.

Khalid Ishaque, Chief Executive Officer of Pixium Vision, said: “In Pixium’s mission to create a world of bionic vision for those with vision loss from retinal dystrophies, the team and partners have delivered a major milestone in the development of its new generation bionic vision system. PRIMA harnesses breakthrough innovations and new possibilities to address a significant unmet need, for which we are concentrating initially in atrophic dry-AMD. We look forward to completing the feasibility phase in France and starting the FDA approved US feasibility study.”

PRIMA Bionic Vision System successfully elicited visual perception thereby rendering demonstration a milestone accomplished.